Insider Transactions in Q4 2024 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2024
|
Samraat S. Raha Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,578
-9.79%
|
$414,092
$14.51 P/Share
|
|
Dec 10
2024
|
Mark Steven Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,816
+50.0%
|
-
|
|
Nov 30
2024
|
Samraat S. Raha Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,118
+0.37%
|
$14,534
$13.83 P/Share
|
|
Oct 11
2024
|
Paul J Diaz President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-1.53%
|
$330,000
$22.93 P/Share
|
|
Oct 09
2024
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,363
-1.41%
|
$200,712
$24.37 P/Share
|
|
Oct 09
2024
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,515
-1.9%
|
$60,360
$24.37 P/Share
|
|
Oct 09
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
452
-0.42%
|
$10,848
$24.37 P/Share
|